ArticleFrontiers in genetics2026
Modified Bixuesan modulates inflammatory and apoptotic gene expression in post-radiotherapy chronic pharyngitis of laryngeal cancer: an integrative network pharmacology and
Article in Frontiers in genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Post-radiotherapy chronic pharyngitis affects 60%-80% of laryngeal cancer survivors and is characterized by sustained elevation of pro-inflammatory cytokines and dysregulation of key apoptotic and oncogenic signaling pathways, including NF-κB/PI3K-AKT/EGFR and TP53/CASP3 axes. Modified Bixuesan (MBS), a classical Traditional Chinese Medicine formula with nearly 180 years of clinical use in pharyngolaryngeal disorders, has not been systematically characterized for its molecular mechanism of action in this context. Methods: We conducted an integrative study combining network pharmacology, multi-omics bioinformatics, and Results: Network pharmacology identified 47 active MBS compounds and 89 putative therapeutic targets, with TP53, AKT1, EGFR, NF-κB1, CASP3, MMP9, and VEGFA as principal hub genes. Molecular docking revealed strong predicted binding of quercetin to TP53 (-9.4 kcal/mol) and kaempferol to EGFR (-8.7 kcal/mol). Conclusion: This integrative study provides
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.